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Transepithelial Corneal Cross-Linking With Vitamin
E-Enhanced Riboflavin Solution and Abbreviated,
Low-Dose UV-A: 24-Month Clinical Outcomes
Ciro Caruso, MD,* Carmine Ostacolo, PharmD,† Robert L. Epstein, MD,‡
Gaetano Barbaro, EngD,§ Salvatore Troisi, MD,¶ and Decio Capobianco, MDk
Purpose: To report the clinical outcomes with 24-month follow-up
of transepithelial cross-linking using a combination of a D-alpha-
tocopheryl polyethylene-glycol 1000 succinate (vitamin E-TPGS)-
enhanced riboﬂavin solution and abbreviated low ﬂuence
UV-A treatment.
Methods: In a nonrandomized clinical trial, 25 corneas of 19
patients with topographically proven, progressive, mild to moderate
keratoconus over the previous 6 months were cross-linked, and all
patients were examined at 1, 3, 6, 12, and 24 months. The treatments
were performed using a patented solution of riboﬂavin and vitamin
E-TPGS, topically applied for 15 minutes, followed by two 5-minute
UV-A treatments with separate doses both at ﬂuence below 3 mW/
cm2 that were based on preoperative central pachymetry.
Results: During the 6-month pretreatment observation, the average
Kmax increased by +1.99 6 0.29 D (diopter). Postoperatively,
the average Kmax decreased, changing by 20.55 6 0.94 D, by
20.88 6 1.02 D and by 21.01 6 1.22 D at 6, 12, and 24 months.
Postoperatively, Kmax decreased in 19, 20, and 20 of the 25 eyes at 6
months, 12 months, and 24 months, respectively. Refractive cylinder
was decreased by 3 months postoperatively and afterward, changing
by 21.35 6 0.69 D at 24 months. Best spectacle-corrected visual
acuity (BSCVA) improved at 6, 12, and 24 months, including an
improvement of 20.19 6 0.13 logarithm of the minimum angle of
resolution units at 24 months. There was no reduction in endothelial
cell count. No corneal abrasions occurred, and no bandage contact
lenses or prescription analgesics were used during postoperative
recovery.
Conclusions: Transepithelial cross-linking using the riboﬂavin-
vitamin E solution and brief, low-dose, pachymetry-dependent UV-
A treatment safely stopped keratoconus progression.
Key Words: corneal cross-linking, transepithelial cross-linking,
keratoconus
(Cornea 2015;0:1–6)
Corneal collagen cross-linking (CXL) was ﬁrst described in1998 by Spoerl et al1 with ﬁrst clinical results reported by
Wollensak et al.2,3 Long-term treatment outcomes in kerato-
conus have been reported4–7 with results now out to 10 years
postoperatively.8 Corneal curvature results have been reported
using Scheimpﬂug photography9 and the Orbscan II (Bausch &
Lomb, Bridgewater, NJ).10 The Dresden protocol, a current
cross-linking standard treatment,2 involves the removal of
corneal epithelium (epi-off technique) followed by 30 minutes
of riboﬂavin corneal soaking and 30 minutes of UV-A
irradiation at 3 mW/cm2.
Cross-linking with epithelium removed, although effec-
tive, is associated with postoperative discomfort, the risk of
sterile corneal inﬁltrates, the typical use of a bandage contact
lens for pain relief, and the risk of corneal ulcer formation.11–13
Attempted riboﬂavin/UVA cross-linking without removing the
epithelium, so-called “transepithelial cross-linking” (TE-CXL),
has not been effective because riboﬂavin barely passes any
concentration into the corneal stroma.
Cross-linking using riboﬂavin with added chemical
permeation enhancers to partially breakup the corneal epithe-
lium to increase riboﬂavin penetration has met with only limited
success.14,15 TE-CXL with riboﬂavin enhanced with trometamol
(TRIS) and EDTA failed to stabilize keratoconus in a 24-month
study.16 But adding an iontophoresis technique to the TRIS/
EDTA-augmented riboﬂavin solution during the presoak period
and using 10 mW/cm2 ﬂuence UV-A irradiation have produced
encouraging early cross-linking results.17 The iontophoresis
technique still requires the use of a postoperative contact lens,
with its attendant risks, and the use of analgesics.
We report in this TE-CXL clinical study the use of
a patented riboﬂavin solution18 that is enhanced with
D-alpha-tocopheryl polyethylene-glycol 1000 succinate
Received for publication June 7, 2015; revision received September 14, 2015;
accepted October 13, 2015.
From the *Corneal Transplant Center, Pellegrini Hospital, Naples, Italy;
†Department of Pharmacy, University of Naples Federico II, Naples, Italy;
‡Mercy Center for Corrective Eye Surgery, McHenry, IL; §I.R.O.S.
(Institute of Refractive and Ophthalmic Surgery), Naples, Italy; ¶Depart-
ment of Ophthalmology, Salerno University Hospital, Salerno, Italy; and
kOphthalmic Center Med Laser Caserta, Caserta, Italy.
The work described here was entirely self-funded by I.R.O.S.
R. L. Epstein has received consultation fees from I.R.O.S. in the past,
although not for the preparation of this article. C. Caruso and S. Troisi are
owners of patent EP 2459 186B1 concerning the vitamin E-TPGS–
enhanced riboﬂavin solution used in this work. The remaining authors
have no conﬂicts of interest to disclose.
Reprints: Robert L. Epstein, MD, Mercy Center for Corrective Eye Surgery, 5400
West Elm St, Suite 120, McHenry, IL 60050 (e-mail: rlepstein@aol.com).
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. This is an
open access article distributed under the terms of the Creative Commons
Attribution-NonCommercial License 4.0 (CC BY-NC), which permits
downloading, sharing, and reproducing the work in any medium,
provided it is properly cited. The work cannot be used commercially.
Cornea  Volume 0, Number 0, Month 2015 www.corneajrnl.com | 1
(vitamin E-TPGS). Ostacolo et al19 reported in detail in vitro
testing in which effective stromal concentrations of riboﬂa-
vin occurred after just 15 minutes of topical application
through intact epithelium. In the technique here reported, the
presoak period was 15 minutes, and the UV-A treatment to
the intact cornea was just 10 minutes with a ﬂuence level at
less than half the UV-A ﬂuence of the original Dresden
protocol. The precorneal riboﬂavin ﬁlm was rinsed away
before UV-A treatment. The results for a group of 25
consecutive eyes of 19 patients are reported with 2-
year follow-up.
MATERIALS AND METHODS
This clinical, prospective, nonrandomized study was
conducted according to the ethical standards of the Declara-
tion of Helsinki (revised in 2000). The patients were informed
about the nature and the aim of experimentation, and they
signed an informed consent. Institutional Review Board
(IRB)/Ethics Committee approval was obtained (authoriza-
tion no. 1269).
Nineteen patients (11 male, 8 female), were enrolled
for treatment, for a total of 25 eyes (13 right eyes, 12 left
eyes, 15 eyes of males, 10 eyes of females). The mean
patient age was 26.7 6 7.4 years. Patient demographics
along with mean clinical parameters are reported in Table 1.
All eyes were affected by keratoconus and were
selected for treatment because of proven Orbscan IIz
topographic progression during the 6 months before treatment
based on an increase in Kmax of over 1.5 D (diopter).
Exclusion criteria included any of the following (1) age below
16 years or above 45 years, (2) evidence of clinical and
instrumental stability of keratoconus in the last 6 months, (3)
thinnest corneal point less than 350 mm, (4) corrected visual
acuity worse than 0.5, (5) evidence of subepithelial or mid-
anterior stromal scars or opacities, (6) evidence of marked
Vogt striae, (7) associated corneal diseases, (8) previous
ocular surgical procedures, (9) wearing of contact lenses in
the 4 weeks before examination, (10) pregnancy or breast
feeding, and (11) poor compliance.
Clinical observations were recorded and are reported
for 6 months before and 1 week before TE-CXL and at 1, 3, 6,
12, and 24 months after treatment.
Examinations included the following: uncorrected visual
acuity and best spectacle-corrected distance visual acuity,
measured in mesopic condition with a logarithm of the mini-
mum angle of resolution chart, refraction, Orbscan IIz corneal
topography with measured sim K at the 3 mm optical zone—
Kmax, Kmin, Kmean, slit-lamp examination of the anterior
and posterior segment, Goldmann tonometry, endothelial
corneal cell count (Tomey EM-3000; Tomey Corp, Japan),
and central corneal thickness measured with ultrasound
(Quantel Medical, Clermont-Ferrand, France). Three days
before treatment, 1 drop of preservative-free norﬂoxacin
0.3% solution was instilled into the operative eye every 6
hours. Twenty minutes before treatment, the anesthetic oxy-
buprocaine hydrochloride 0.2% (Minims—Bausch & Lomb,
London), a single-use, preservative-free, sterile topical solu-
tion, was instilled at the rate of 2 drops every 5 minutes. One
drop of norﬂoxacin 0.3% (Naﬂox 0.3%; Farmigea, Italy)
single-use, preservative-free, sterile topical solution was
instilled every 3 minutes for antibiotic prophylaxis, and 2
drops of pilocarpine 1% (pilocarpine hydrochloride 1%;
Allergan, Dublin, Ireland) were instilled.
Periocular skin was then disinfected with povidone
iodine 10% solution. For the corneal presoaking, a Landers
vitrectomy silicone ring (12 mm diameter, 3 mm height
Ocular Instruments Inc., Bellevue, WA) was placed on the
corneoscleral limbus (Fig. 1) to retain the riboﬂavin solution,
composed of riboﬂavin-dextran 0.1 g/100 g and vitamin
E-TPGS 500 mg/100 mL, (IROS, Naples, Italy). Drops of this
solution were delivered into the silicone ring to completely
cover the cornea. Filled with solution, the ring was main-
tained in place for 15 minutes. Further drops were added as
necessary to maintain corneal coverage with the solution.
After the corneal presoak, a slit-lamp examination was then
performed to observe the complete yellow dying of corneal
tissue and the greenish Tyndall effect in the anterior chamber
with a blue ﬁlter, indicating adequate passage of the
riboﬂavin solution.
TABLE 1. Patient Demographics (n = 25)
Age 26.3 6 8.3
Male/female 15/10
Corrected distance acuity (logMAR) (BSCVA) 0.10 6 0.13
Spherical equivalent 24.70 6 3.38
Refractive cylinder 3.25 6 1.58
Maximum keratometry (6 months pre-CXL) 47.65 6 5.22
Maximum keratometry (1 wk pre-CXL) 49.64 6 5.20
Mean K (6 months pre-CXL) 46.82 6 4.67
Mean K (1 wk pre-CXL) 47.83 6 4.66
Minimum corneal thickness (6 months pre-CXL) 461.0 6 56.3
Minimal corneal thickness (1 wk pre-CXL) 456.0 6 56.6
Endothelial cell density (1 wk pre-CXL) 2549 6 263
logMAR, logarithm of the minimum angle of resolution; BSCVA, best spectacle-
corrected visual acuity.
FIGURE 1. Silicone ring during corneal presoak.
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The power of the emitter used to irradiate the corneas
(Vega CBM X-Linker; CSO, Italy) was lowered from the usual
3 mW/cm2 ﬂuence with partially absorbing UV-ﬁlters (Knight
Optical LTD, United Kingdom), to achieve a customized-
delivered power, according to the nomogram from our
mathematical model described by Barbaro et al.20 That nomo-
gram speciﬁes a UV-A ﬂuence that is pachymetry dependent
and at a level lower than that speciﬁed in the Dresden protocol.
The intraoperative UV ﬂuence measurements were performed
with a LaserMateQ, (Coherent Inc, Santa Clara, CA). The
treatment diameter was 8 mm at a distance of 5 cm from the
corneal apex. During the ﬁrst 5 minutes, the average UV-A
ﬂuence applied was 1.67 6 0.08 mW/cm2; during the second
5 minutes, the average UV-A ﬂuence applied was 1.45 6 0.08
mW/cm2. There was no time break between the ﬁrst UV-A
treatment and the second treatment except for the time
necessary to change the UV-A ﬂuence level.
No more riboﬂavin solution was applied during the
UV-A exposure. Rather, the corneal surface was washed with
balanced salt solution to remove the superﬁcial riboﬂavin ﬁlm
before irradiation. Drops of balanced salt solution were
delivered onto the corneal surface during UV exposure to
maintain adequate moisture. Norﬂoxacin 0.3% eye drops
were administered at the end of the treatment.
The patients returned home with topical antibiotic and
lubricant therapy (norﬂoxacin 0.3% and hyaluronate 0.15%
eye drops every 6 hours), and these drops were used just until
the following day. No analgesics were prescribed. There was
no use of a bandage contact lens postoperatively.
RESULTS
Patient discomfort did not require the use of pre-
scription pain relievers. There were no corneal abrasions.
We noticed 1 case of transient corneal haze and 2 cases of
transient stromal edema; these were managed with topical
corticosteroid therapy, with complete clinical resolution after
a few weeks. Mild epithelial edema was sometimes present
soon after the treatment but disappeared in all cases within
a few days. The clinical outcomes of the TE-CXL treatment
are reported in Table 2.
A statistically signiﬁcant improvement of corneal,
refractive, and visual acuity parameters was evident after
treatments (P , 0.05 calculated with the Student t test, using
the pretreatment values as reference) in best spectacle-
corrected visual acuity at 6, 12, and 24 months (P = 0.01,
P , 0.01, and P = 0.02, respectively) and in refractive
cylinder at 12 and 24 months (P = 0.03, P , 0.01, and P =
0.02, respectively), compared with pretreatment values. There
was also a statistically signiﬁcant decrease of the Kmean at 12
and 24 months compared with pretreatment values. There was
stabilization of Kmax. During the 6-month pretreatment
observation, all 25 eyes had keratoconus progression with
increased Kmax. The average pretreatment Kmax increase
was 1.99 6 0.29 D. After TE-CXL treatment, Kmax
decreased compared with the 1-week preoperative value in
19, 20, and 20 of the 25 eyes at 6 months, 12 months, and 24
months (P = 0.04, 0.03, and 0.03, respectively). A graph
showing the behavior of Kmax is depicted in Figure 2.
A stabilization of corneal and refractive parameters was
observed in all cases. Average best spectacle-corrected visual
acuity was 0.79 at 1 week preoperatively, 0.79 at 1 month
postoperatively (P = 0.91), and 0.97 (P = 0.02) at 2 years
postoperatively. The average preoperative endothelial cell
count was 2549 6 263; at 2 years postoperatively it was
2548 6 270 (P = 0.97). Average refractive cylinder was
reduced (P , 0.01) from a preoperative value of 3.25 6 1.58
D to 2-year postoperative value of 1.90 6 1.51 D. Spherical
equivalent decreased (P , 0.01) from 24.70 6 3.38 D
preoperatively to 23.50 6 3.10 D at 2 years postoperatively.
Kmax averaged 47.6 6 5.2 D at 6 months preoperatively,
progressed to 49.6 6 5.2 D at 1 week postoperatively, and
was 48.5 6 4.4 D at 2 years postoperatively (P = 0.03).
Average central corneal thickness, 456 6 56.6 mm at 1
week preoperative, decreased to a minimum of 427.9 6 54.9
mm at 3 months postoperative and increased to 462.6 6 46.8
mm at 24 months postoperatively (P = 0.61). Further
pachymetry data appear in Table 2.
Intraocular pressure was unchanged (P = 0.808) at 1
year postoperatively (15.6 6 1.6 mm Hg) as compared with
preoperative levels (15.6 6 2.0 mm Hg).
DISCUSSION
The results of this clinical trial are encouraging,
considering that clinical stabilization of keratoconus
TABLE 2. Clinical Outcomes of Transepithelial Corneal Collagen Cross-linking With Riboflavin–Vitamin E-TPGS
Parameters
Difference From Values at 1 Week Preoperative, n = 25, Mean 6 SD
1 mo 3 mo 6 mo 12 mo 24 mo
Refractive parameters
Corrected distance acuity (logMAR) 20.004 6 0.17 20.05 6 0.10 20.092 6 0.89 20.11 6 0.09 20.09 6 0.11
Spherical equivalent 0.06 6 0.20 0.32 6 0.50 0.50 6 0.58 0.60 6 0.54 1.21 6 0.70
Refractive cylinder magnitude 20.02 6 0.23 20.28 6 0.43 20.73 6 0.48 20.95 6 0.47 21.35 6 0.69
Topographical parameters
Maximum keratometry 0.36 6 0.71 0.09 6 0.78 20.55 6 0.94 20.88 6 1.02 21.10 6 1.22
Mean K 0.32 6 0.61 0.12 6 0.73 20.35 6 0.90 20.58 6 0.99 20.59 6 1.13
Minimum corneal thickness 229.2 6 17.7 228.1 6 18.1 217.1 6 18.0 28.8 6 17.7 6.6 6 24.0
logMAR, logarithm of the minimum angle of resolution.
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progression was obtained in all cases and lasted for 24 months
without remarkable side effects.
The treatment yielded signiﬁcant improvement in corneal
topography and visual acuity although the study involved
relatively mild cases of keratoconus. Generally, cross-linking
induces less effect in cases of mild keratoconus than in the
more advanced cases.21 The eyes treated in this study were
topographically proven cases of keratoconus, but at a much
milder stage (Average preoperative Kmax = 49.64 D) when
compared with more typical cross-linking study populations
reported, such as Caporossi et al4 (average preoperative Kmax =
51.72 D), Coskunseven5 (Average preoperative Kmax = 54.02
D), Raiskup et al8 (Average preoperative Kmax = 53.2 D), and
Vinciguerra et al17 (Average preoperative Kmax = 59.02 D).
We look forward to further testing of this new technique in
more advanced keratoconus cases.
In contrast to the Dresden protocol, in this study, the
excess of riboﬂavin solution, derived from the corneal
presoaking, was washed off before UV-A irradiation, thus
avoiding superﬁcial UV-A shielding. In this way, the UV-A
ﬂuence could be reduced almost to 1.5 mW/cm2, maintaining
efﬁcacy. This approach was suggested by our in vitro studies
and is currently submitted for publication. The same studies
revealed that the endothelial shielding effect of intracorneal
riboﬂavin rapidly fades, with time, during UV-A irradiation,
at a typical rate. Thus, lower UV-A ﬂuence during the second
5-minute treatment period was used.
The UV-A ﬂuence was also modulated on the average
corneal thickness determined by pachymetry measured 1 week
preoperatively. In this way, the UV-A rays reaching the
endothelium were more easily maintained below the endo-
thelial toxicity levels as described by Wollensak.22
It must be also considered how this approach makes the
cross-linking technique more reproducible in comparison
with standard techniques, where riboﬂavin is continually
placed during UV-A irradiation. The periodic application of
undeﬁned amounts of riboﬂavin during treatments, in fact,
could be responsible for a different superﬁcial UV-A ﬁltering
and, ﬁnally, for a different efﬁcacy.
Total treatment time was reduced to 25 minutes (15 mi-
nutes of presoak and 10 minutes of UV-A treatment) versus
60 minutes (30 minutes of presoak and 30 minutes of UV-A
treatment) in the Dresden protocol, and the decreased power of
UV-A irradiation led to rapid recovery of corneal epithelium
with no detectable damage to the corneal endothelium.
The total applied UV-A energy over the treatment
period in this study was approximately 1.5 mW/cm2 for
10 minutes or only 0.9 J/cm2 in our clinical trial. This
compares with 5.4 J/cm2 in the Dresden protocol. We believe
that, in addition to the increased efﬁciency of light trans-
mission to the cornea in our study achieved by eliminating the
precornea riboﬂavin ﬁlm, it is likely that riboﬂavin entered
the cornea more efﬁciently because of the use of the Landers
vitrectomy silicone ring. That increased riboﬂavin penetration
achieved by continuous soaking was studied and reported by
Schumacher et al.23
In our study, patients were prudently treated with
antibiotic drops before treatment because the chance of
FIGURE 2. Average Kmax value 6 1 SD over time 6 months and 1 week before corneal cross-linking and then at follow-up
examinations at 1 month, 3 months, 6 months, 1 year, and 2 years postoperatively.
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corneal epithelial breaks was unpredictable. Based on the
experience gained during this study and on the here reported
absence of epithelial damage, we would now eliminate
preoperative topical antibiotic treatment.
Importantly, keratoconus stabilization with cross-
linking has been achieved in this study without removal or
disturbance of the corneal epithelium. This has led to a more
rapid and comfortable visual recovery with lower risk
of complications.
The results obtained are further encouraging in light of
the evidence that inadequate cross-linking effect can be
augmented by further treatment.24 Thus, it becomes increas-
ingly important to produce a cross-linking treatment charac-
terized by minimal risk and maximal compliance.
The correct diagnosis of keratoconus progression
depends on the reproducibility of topographic measurements.
Menassa et al25 found that the variance in Kmax measure-
ments in normal subjects, measured using the Orbscan II, was
equal to that obtained by the Scheimpﬂug system of the
Galilei topographer. Nuñez et al26 found that the Orbscan II
had less variance in determining the point of maximal corneal
elevation than the Pentacam. Kim and Joo27 studied kerato-
conus patients with the Orbscan every 6 months, assessing as
nonprogressive the changes in average keratometry within
+0.156 0.15 D per 6-month period. Epstein et al28 found that
the 95% conﬁdence level of true change in maximal anterior
corneal curvature, Kmax, based on single measurements at
each session was 1.51 D using the Pentacam HR. Based on
these topographer reproducibility ﬁndings, a conservative
estimate of the 95% conﬁdence level of keratoconus pro-
gression using the Orbscan II could be set at 1.51 D, that of the
Pentacam HR, because the articles cited here tended to indicate
that the Orbscan II is as reproducible as Scheimpﬂug
topography. Hence, all 25 eyes in our study reached the 95%
conﬁdence level of true keratoconus progression before
treatment and none reached 95% conﬁdence of further pro-
gression at 2 years postoperatively. In fact, 20 of the 25 eyes in
the study showed a decrease in Kmax at 2 years postopera-
tively as compared with the 1 week preoperative Kmax value.
The statistical power of our experimental model was
challenged by a matched, paired Student t test. We took the
data from the left eye of each patient who had 2 eyes cross-
linked and the data from each patient who had only 1 eye
cross-linked. The population was composed of 19 patients. The
null hypothesis was that the proposed cross-linking treatment
was ineffective, not determining a stop in Kmax increase. The
post hoc power of our model to correctly reject the null
hypothesis with 95% conﬁdence, 19 independent variables and
average decreases in measured Kmax of 0.8816 at 1 year and
1.1395 at 2 years, is 90.25% and 95.3%, respectively.
One shortcoming of the present clinical study is the lack
of a placebo group. Nevertheless, other important cross-
linking clinical studies in the published literature, such as
those by Caporossi et al16 and Vinciguerra et al,17 have not
included a placebo group.
A prospective randomized, double masked, placebo-
controlled clinical trial of cross-linking using riboﬂavin–
vitamin E-TPGS under the US Food and Drug Administration
monitoring is in progress. The Food and Drug Administration-
monitored clinical trial is in 2 parts. The ﬁrst study is to test the
effectiveness of TE-CXL with riboﬂavin–vitamin E-TPGS
with presoaking times and UV-A exposure times equal to
those of the Dresden protocol. The second study is to test the
effect of shortened UV-A exposure times and presoaking times
as described in this article.
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